As such, PIK3CA mutation in CRC has been reported as a predictive molecular biomarker for adjuvant aspirin therapy [74]; however, confirmatory prospective studies need to be carried out to confirm this hypothesis. This evidence concerns the gene PIK3CA and colorectal carcinoma.